| Shah, Manish A |
| Recruiting | 3 | 400 | US | FOLFIRI Protocol, FOLinic acid-Fluorouracil-IRInotecan regimen, ACTIVE SURVEILLANCE, Nivolumab Protocol, Nivolumab, Encorafenib/Binimetinib/Cetuximab Protocol, Enco/Bini/Cetux, Trastuzumab + Pertuzumab, Herceptin | Massachusetts General Hospital, Stand Up To Cancer | Metastatic Colon Cancer, Stage III Colon Cancer | 12/26 | 12/27 | | |
| Recruiting | 3 | 6000 | US | Standardized seizure protocol, midazolam, Conventional seizure protocol | Stanford University, National Institute of Neurological Disorders and Stroke (NINDS), University of Utah, Baylor College of Medicine | Seizures | 07/26 | 09/26 | | |
A022102, NCT05677490: MFOLFIRINOX Versus MFOLFOX with or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma |
|
|
| Recruiting | 3 | 382 | US | Fluorouracil, 2,4-Dioxo-5-fluoropyrimidine, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluoro-2,4(1H,3H)-pyrimidinedione,, Leucovorin Calcium, 1492-18-8, 5-Formyl Tetrahydrofolate, Calcium (6S)-Folinate, Calcium Folinate, Oxaliplatin, 1-OHP, Dacotin, Dacplat, ELOXATIN, Irinotecan, Nivolumab, MDX-1106, Opdivo, Magnetic Resonance Imaging, MRI, Computed Tomography, CAT Scan, Computed Axial Tomography, CT Scan, Biospecimen Collection, Questionnaire Administration | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC V8, Clinical Stage III Gastric Cancer AJCC V8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC V8, Clinical Stage IV Esophageal Adenocarcinoma AJCC V8, Clinical Stage IV Gastric Cancer AJCC V8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC V8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma | 11/28 | 11/28 | | |
NCT03146962: High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies |
|
|
| Completed | 2 | 61 | US | Vitamin C, Ascorbic Acid | Weill Medical College of Cornell University, Stand Up To Cancer | Colorectal Cancer, Pancreatic Cancer, Lung Cancer | 04/23 | 04/23 | | |
NCT03921021: Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma |
|
|
| Completed | 2 | 17 | US | Telomelysin, OBP-301 | Weill Medical College of Cornell University, Oncolys BioPharma Inc | Esophagogastric Adenocarcinoma | 06/23 | 07/23 | | |
NCT02998268: Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma |
|
|
| Active, not recruiting | 2 | 42 | US | Pembrolizumab, Keytruda, Taxol, Paclitaxel, Carboplatin | Weill Medical College of Cornell University, Merck Sharp & Dohme LLC | Esophageal Adenocarcinoma | 02/21 | 09/26 | | |
CA209-76L, NCT04021108: Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol ) |
|
|
| Active, not recruiting | 2 | 80 | US | Nivolumab 240 MG | Weill Medical College of Cornell University, Bristol-Myers Squibb | Gastroesophageal Adenocarcinoma | 04/25 | 04/26 | | |
NCT06300463: Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases |
|
|
| Recruiting | 2 | 24 | US | Botensilimab, AGEN1181, Balstilimab, AGEN2034, AGEN1423, Radiation | Weill Medical College of Cornell University, Agenus Inc. | Colorectal Cancer Metastatic, Liver Metastases, Colorectal Cancer | 09/25 | 03/27 | | |
NCT06340711: Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma |
|
|
| Recruiting | 2 | 27 | US | OBP-301, Suratadenoturev, Pembrolizumab, Keytruda | Weill Medical College of Cornell University, Merck Sharp & Dohme LLC, Oncolys BioPharma Inc | Esophageal Adenocarcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 04/26 | 04/28 | | |
| Terminated | 2 | 205 | Europe, US, RoW | ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda | Seagen Inc., Merck Sharp & Dohme LLC | Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma | 11/23 | 11/23 | | |
NCT05480384: Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction |
|
|
| Recruiting | 2 | 25 | US | Nivolumab, OPDIVO, Trastuzumab deruxtecan, ENHERTU | Brown University, AstraZeneca | Esophageal Adenocarcinoma, Esophageal Cancer, HER-2 Protein Overexpression, Gastroesophageal-junction Cancer | 01/25 | 01/27 | | |
| Active, not recruiting | 1/2 | 115 | Europe, Canada, US | GAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose, MVA-209-FSP high dose, GAd20-209-FSP, RP2D, MVA-209-FSP, RP2D, KEYTRUDA®, pembrolizumab | Nouscom SRL, Merck Sharp & Dohme LLC | Solid Tumor, Adult | 04/25 | 11/26 | | |
KISIMA-01, NCT04046445: Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer |
|
|
| Active, not recruiting | 1 | 96 | Europe, US | ATP128, BI 754091, Ezabenlimab, VSV-GP128 | Amal Therapeutics, Boehringer Ingelheim | Colorectal Cancer, MSS, Stage IV Colon Cancer, Stage IV Rectal Cancer, Metastatic Colorectal Cancer, Liver Metastasis Colon Cancer | 05/25 | 08/25 | | |
| Recruiting | N/A | 240 | US | | Omron Healthcare Co., Ltd., University of Wisconsin, Madison, Children's Hospital Medical Center, Cincinnati, University of Chicago | Asthma in Children, Bronchitis, Bronchiolitis | 11/21 | 12/21 | | |
| Active, not recruiting | N/A | 153 | US | Standard Cryoballoon Pulmonary Vein Isolation (PVI), Arctic Front Advance Cardiac Cryoablation System, Cryoballoon PVI + Posterior Wall Isolation | Dignity Health Medical Foundation, Mercy General Hospital and Dignity Health Medical Foundation, Beth Israel Deaconess Medical Center, UC Health Medical Center, MedStar Georgetown University Hospital and Medical Center, Tampa Cardiac Specialists, Bethesda North Hospital, Brigham and Women's Hospital, Texas Cardiac Arrhythmia Institute At St. Davids Medical Center, St. Luke's Hospital and Health Network, Pennsylvania, Sarasota Memorial Health Care System, Nebraska Methodist Hospital-Methodist Physicians Clinic | Persistent Atrial Fibrillation | 04/24 | 12/24 | | |
| Active, not recruiting | N/A | 949 | US | WATCHMAN FLX Pro LAAC Device, Left Atrial Appendage Closure | Boston Scientific Corporation | Atrial Fibrillation, Bleeding, Stroke | 07/24 | 08/25 | | |
| Recruiting | N/A | 2650 | Europe, Canada, Japan, US, RoW | Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder), Amplatzer Amulet LAA Occluder, Non-Vitamin K Oral Antagonists, NOAC | Abbott Medical Devices | Atrial Fibrillation, Stroke, Bleeding | 08/27 | 08/30 | | |
NCT02164409: Changes Associated With H. Pylori and Gastric Carcinogenesis |
|
|
| Recruiting | N/A | 120 | US | Endoscopy tissue collection | Weill Medical College of Cornell University | Bacterial Infection Due to Helicobacter Pylori (H. Pylori) | 04/25 | 04/25 | | |
NCT02535936: Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy |
|
|
| Recruiting | N/A | 15 | US | 3Tesla MRI with DTI-MRI and rsfcMRI under general anesthesia | The University of Texas Health Science Center, Houston | Spastic Diplegia | 01/30 | 01/31 | | |
DTI/SEP, NCT02846272: Diffusion Tensor and Functional Connectivity Imaging in Pediatric Epilepsy: Imaging/Histology Correlation |
|
|
| Recruiting | N/A | 50 | US | Observation | The University of Texas Health Science Center, Houston | Intractable Epilepsy | 01/30 | 01/31 | | |
| Sandberg, David |
NCT04269343: Infusion of Panobinostat (MTX110) Into the Fourth Ventricle or Tumor Resection Cavity in Children and Adults With Recurrent Medulloblastoma |
|
|
| Not yet recruiting | 1 | 5 | US | Treatment with MTX110 | The University of Texas Health Science Center, Houston | Medulloblastoma | 12/22 | 12/22 | | |
NCT06466798: Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies |
|
|
| Recruiting | 1 | 10 | US | Nivolumab, Methotrexate, 5-Azacytidine | David Ilan Sandberg | Recurrent Ependymoma, Recurrent Medulloblastoma, CNS Malignancies | 07/27 | 07/27 | | |
HSC-MS-21-0231, NCT04958486: Combination Intraventricular Chemotherapy Pilot Study: 5-Azacytidine (5-AZA) and Trastuzumab Infusions Into the Fourth Ventricle or Resection Cavity in Children and Adults With Recurrent or Residual Posterior Fossa Ependymoma |
|
|
| Recruiting | 1 | 10 | US | 5-Azacytidine and trastuzumab infusion | The University of Texas Health Science Center, Houston | Fossa Ependymoma | 12/25 | 12/25 | | |
NCT02905110: Methotrexate and Etoposide Infusions Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Brain Tumors |
|
|
| Recruiting | 1 | 10 | US | Methotrexate, Trexall, Rasuvo, Etoposide, VePesid, Toposar, Etopophos, Ommaya Reservoir | The University of Texas Health Science Center, Houston | Brain Tumor Recurrent | 11/25 | 11/25 | | |
NCT03572530: Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa Ependymoma |
|
|
| Recruiting | 1 | 9 | US | 5-Azacytidine (5-AZA) group 1, Vidaza, 5-Azacytidine (5-AZA) group 2, 5-Azacytidine (5-AZA) group 3 | The University of Texas Health Science Center, Houston | Recurrent Ependymoma | 12/25 | 12/25 | | |
NCT04315064: Infusion of Panobinostat (MTX110) Into the Fourth Ventricle in Children and Adults With Recurrent Medulloblastoma |
|
|
| Recruiting | 1 | 5 | US | Treatment with MTX110 | The University of Texas Health Science Center, Houston, Midatech Pharma plc | Medulloblastoma | 12/25 | 12/25 | | |
| Yu, Bangning |
NCT06466798: Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies |
|
|
| Recruiting | 1 | 10 | US | Nivolumab, Methotrexate, 5-Azacytidine | David Ilan Sandberg | Recurrent Ependymoma, Recurrent Medulloblastoma, CNS Malignancies | 07/27 | 07/27 | | |
HSC-MS-21-0231, NCT04958486: Combination Intraventricular Chemotherapy Pilot Study: 5-Azacytidine (5-AZA) and Trastuzumab Infusions Into the Fourth Ventricle or Resection Cavity in Children and Adults With Recurrent or Residual Posterior Fossa Ependymoma |
|
|
| Recruiting | 1 | 10 | US | 5-Azacytidine and trastuzumab infusion | The University of Texas Health Science Center, Houston | Fossa Ependymoma | 12/25 | 12/25 | | |
NCT02905110: Methotrexate and Etoposide Infusions Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Brain Tumors |
|
|
| Recruiting | 1 | 10 | US | Methotrexate, Trexall, Rasuvo, Etoposide, VePesid, Toposar, Etopophos, Ommaya Reservoir | The University of Texas Health Science Center, Houston | Brain Tumor Recurrent | 11/25 | 11/25 | | |
NCT03572530: Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa Ependymoma |
|
|
| Recruiting | 1 | 9 | US | 5-Azacytidine (5-AZA) group 1, Vidaza, 5-Azacytidine (5-AZA) group 2, 5-Azacytidine (5-AZA) group 3 | The University of Texas Health Science Center, Houston | Recurrent Ependymoma | 12/25 | 12/25 | | |
NCT04315064: Infusion of Panobinostat (MTX110) Into the Fourth Ventricle in Children and Adults With Recurrent Medulloblastoma |
|
|
| Recruiting | 1 | 5 | US | Treatment with MTX110 | The University of Texas Health Science Center, Houston, Midatech Pharma plc | Medulloblastoma | 12/25 | 12/25 | | |
NCT02535936: Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy |
|
|
| Recruiting | N/A | 15 | US | 3Tesla MRI with DTI-MRI and rsfcMRI under general anesthesia | The University of Texas Health Science Center, Houston | Spastic Diplegia | 01/30 | 01/31 | | |
DTI/SEP, NCT02846272: Diffusion Tensor and Functional Connectivity Imaging in Pediatric Epilepsy: Imaging/Histology Correlation |
|
|
| Recruiting | N/A | 50 | US | Observation | The University of Texas Health Science Center, Houston | Intractable Epilepsy | 01/30 | 01/31 | | |
